Navigation Links
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Date:6/30/2008

Conference Call and Webcast Today at 1:00 pm ET / 10:00 am PT

SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has launched its first commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. Zingo is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous (IV) line placements and blood draws in children three to 18 years of age. Zingo works quickly, within one to three minutes, to relieve pain at the needle insertion site.

"Zingo is the first easy-to-administer, fast-acting local anesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said William T. Zempsky, M.D., Associate Professor, Department of Pediatrics, University of Connecticut; Associate Director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the pediatric trials of Zingo. "Because available topical anesthetic creams can take up to 30 to 60 minutes to work, healthcare providers have had to sacrifice patient comfort when performing the numerous peripheral venous access procedures that occur each day. Zingo will be a source of relief to both them and the children and parents they deal with every day."

"The commercial launch of Zingo is a major milestone that is notable both for our company and for patients. We are fully committed to driving successful market introduction for this exciting new product," said Michael L. Kranda, Anesiva's president and chief executive officer.

Driving Penetration and Uptake for Large Unmet Need

"We are initially focusing
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended June 30, 2015. ... dollars and presented under International Financial Reporting Standards ... respect to our Oral Amp B program, rapidly ... said Andrew Rae , President & CEO ...
(Date:8/26/2015)... 2015 Intrexon Corporation (NYSE: XON ), ... of its previously announced public offering of common stock, ... their option to purchase an additional 731,707 shares of ... per share.  The exercise of the underwriters, option brought ... by Intrexon to 5,609,756 shares and increased the total ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Corp . President Paul Shain spoke on his ... Madisons monthly meeting. According to Shain, Berbees unique principles and ... dot-com era as other information technology-focused companies failed. , ,Started ... founded on the dogma of creating an environment for success, ...
... Internet access is now a reality for one rural ... system. Toronto-based WaveRider Communications Inc. is working ... Oakdale Electric Cooperative to implement its Last Mile ... to broadband Internet services. , ,The response in Mauston ...
... a talk at my local elementary school given by Peter ... of systems thinking. Systems thinking is a conceptual framework, body ... years, to train people to see the big picture ... how to make systematic change successfully. The essence of systems ...
Cached Biology Technology:Berbees success is based on companys history and culture 2Berbees success is based on companys history and culture 3Berbees success is based on companys history and culture 4Rural Wisconsin town gets high-speed Internet access 2Outsourcing: Net gain or shifting the pain? 2Outsourcing: Net gain or shifting the pain? 3
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 27, 2013  Definiens, the global leader of image and ... it has appointed an Advisory Board comprising renowned industry ... its market expansion strategy, Definiens established the new Board ... tissue diagnostics and clinical digital pathology. Members of the ...
... caffeine, but scientists now have genetically engineered E. ... report in the journal ACS Synthetic Biology ... that promises practical uses ranging from decontamination of wastewater ... Barrick and colleagues note that caffeine and related chemical ...
... and the University of Oxford have been able to give ... provide paternal care. When the conditions are right, this strategy ... put a lot of effort into caring for offspring that ... sense at all because natural selection should design males to ...
Cached Biology News:Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 2Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 3Why sticking around is sometimes the better choice 2
Goat polyclonal to Centaurin alpha 2**...
... immobilization can be coupled with a ligand such ... create an affinity matrix of choice. Affi-Gel 10 ... amines. Affi-Gel 10 gel couples neutral or basic ... 15 gel couples acidic proteins with pI less ...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Monocarboxylate (lactate) transporter 2...
Biology Products: